Literature DB >> 29581538

Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.

Asli Ercan Dogan1, Cagri Yuksel1,2, Fei Du1,2, Virginie-Anne Chouinard1,2, Dost Öngür3,4.   

Abstract

Converging evidence from molecular to neuroimaging studies suggests brain energy metabolism abnormalities in both schizophrenia and bipolar disorder. One emerging hypothesis is: decreased oxidative phosphorylation leading to accumulation of lactic acid from glycolysis and subsequent acidification of tissue. In this regard, integrating lactate and pH data from magnetic resonance spectroscopy (MRS) studies in both diseases may help us understand underlying neurobiological mechanisms. In order to achieve this goal, we performed a systematic search of case-control studies examining brain lactate or pH among schizophrenia and/or bipolar patients by using MRS. Medline/Pubmed and EBSCO databases were searched separately for both diseases and outcomes. Our search yielded 33 studies in total composed of 7 lactate and 26 pH studies. In bipolar disorder, 5 out of 6 studies have found elevated lactate levels especially in the cingulate cortex and 4 out of 13 studies reported reduced pH in the frontal lobe. In contrast, in schizophrenia a single study has examined lactate and reported elevation, while only 2 out of 13 studies examining pH have reported reduction in this measure. There were no consistent patterns for the relationship between lactate or pH levels and medication use, disease type, mood state, and other clinical variables. We highlight the need for future studies combining 1H-MRS and 31P-MRS approaches, using longitudinal designs to examine lactate and pH in disease progression across both schizophrenia and bipolar disorders.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29581538      PMCID: PMC6006165          DOI: 10.1038/s41386-018-0041-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  55 in total

1.  In vivo 31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest.

Authors:  Yukihiko Shirayama; Toshio Yano; Kiyohisa Takahashi; Seizo Takahashi; Takashi Ogino
Journal:  Eur J Neurosci       Date:  2004-08       Impact factor: 3.386

2.  Abnormal frontal lobe phosphorous metabolism in bipolar disorder.

Authors:  R F Deicken; G Fein; M W Weiner
Journal:  Am J Psychiatry       Date:  1995-06       Impact factor: 18.112

3.  Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia.

Authors:  Ganesan Venkatasubramanian; Seetharamaiah Chittiprol; Narendran Neelakantachar; Magadi N Naveen; Jagadisha Thirthall; Bangalore N Gangadhar; K Taranath Shetty
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

4.  Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia.

Authors:  T Kato; T Shioiri; J Murashita; H Hamakawa; T Inubushi; S Takahashi
Journal:  Psychiatry Res       Date:  1995-09-29       Impact factor: 3.222

5.  Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.

Authors:  J Eric Jensen; Melissa Daniels; Charlotte Haws; Nicolas R Bolo; In Kyoon Lyoo; Sujung J Yoon; Bruce M Cohen; Andrew L Stoll; James R Rusche; Perry F Renshaw
Journal:  Exp Clin Psychopharmacol       Date:  2008-06       Impact factor: 3.157

6.  Brain metabolic alterations in medication-free patients with bipolar disorder.

Authors:  Stephen R Dager; Seth D Friedman; Aimee Parow; Christina Demopulos; Andrew L Stoll; In Kyoon Lyoo; David L Dunner; Perry F Renshaw
Journal:  Arch Gen Psychiatry       Date:  2004-05

7.  Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity.

Authors:  T Kato; J Murashita; A Kamiya; T Shioiri; N Kato; T Inubushi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

8.  Clinical response of quetiapine in rapid cycling manic bipolar patients and lactate level changes in proton magnetic resonance spectroscopy.

Authors:  Dajung J Kim; In Kyoon Lyoo; Sujung J Yoon; Taeyoung Choi; Byungchol Lee; Jieun E Kim; Joonsun S Lee; Perry F Renshaw
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-04-24       Impact factor: 5.067

9.  31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics--a study including 50 patients and 36 controls.

Authors:  H P Volz; R Rzanny; G Rössger; G Hübner; I Kreitschmann-Andermahr; W A Kaiser; H Sauer
Journal:  Biol Psychiatry       Date:  1998-09-15       Impact factor: 13.382

10.  Dorsal Anterior Cingulate Lactate and Glutathione Levels in Euthymic Bipolar I Disorder: 1H-MRS Study.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Bruno F Pastorello; Cláudia da Costa Leite; Anke Henning; Ricardo A Moreno; Maria Concepción Garcia Otaduy
Journal:  Int J Neuropsychopharmacol       Date:  2016-08-12       Impact factor: 5.176

View more
  16 in total

1.  What a Clinician Should Know About the Neurobiology of Schizophrenia: A Historical Perspective to Current Understanding.

Authors:  Lynn E DeLisi
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 2.  Targeting Mitochondrial Dysfunction for Bipolar Disorder.

Authors:  Maya Kuperberg; Sophie L A Greenebaum; Andrew A Nierenberg
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 3.  Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia.

Authors:  Narasimha M Beeraka; Marco F Avila-Rodriguez; Gjumrakch Aliev
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

4.  Diagnosis- and Cell Type-Specific Mitochondrial Functional Pathway Signatures in Schizophrenia and Bipolar Disorder.

Authors:  Jill R Glausier; John F Enwright; David A Lewis
Journal:  Am J Psychiatry       Date:  2020-10-29       Impact factor: 18.112

5.  Dose Adjustment of Quetiapine and Aripiprazole for Pregnant Women Using Physiologically Based Pharmacokinetic Modeling and Simulation.

Authors:  Liang Zheng; Shiwei Tang; Rui Tang; Miao Xu; Xuehua Jiang; Ling Wang
Journal:  Clin Pharmacokinet       Date:  2020-11-30       Impact factor: 6.447

6.  Analysis of GWAS-Derived Schizophrenia Genes for Links to Ischemia-Hypoxia Response of the Brain.

Authors:  Rainald Schmidt-Kastner; Sinan Guloksuz; Thomas Kietzmann; Jim van Os; Bart P F Rutten
Journal:  Front Psychiatry       Date:  2020-05-12       Impact factor: 4.157

7.  Transcriptome analysis and functional characterization of cerebral organoids in bipolar disorder.

Authors:  Annie Kathuria; Kara Lopez-Lengowski; Magdalena Vater; Donna McPhie; Bruce M Cohen; Rakesh Karmacharya
Journal:  Genome Med       Date:  2020-04-19       Impact factor: 11.117

Review 8.  The Role of Mitochondria in Mood Disorders: From Physiology to Pathophysiology and to Treatment.

Authors:  Anna Giménez-Palomo; Seetal Dodd; Gerard Anmella; Andre F Carvalho; Giselli Scaini; Joao Quevedo; Isabella Pacchiarotti; Eduard Vieta; Michael Berk
Journal:  Front Psychiatry       Date:  2021-07-06       Impact factor: 4.157

9.  Putative Astroglial Dysfunction in Schizophrenia: A Meta-Analysis of 1H-MRS Studies of Medial Prefrontal Myo-Inositol.

Authors:  Tushar Kanti Das; Avyarthana Dey; Priyadharshini Sabesan; Alborz Javadzadeh; Jean Théberge; Joaquim Radua; Lena Palaniyappan
Journal:  Front Psychiatry       Date:  2018-09-21       Impact factor: 4.157

Review 10.  Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope?

Authors:  Federico E Turkheimer; Pierluigi Selvaggi; Mitul A Mehta; Mattia Veronese; Fernando Zelaya; Paola Dazzan; Anthony C Vernon
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 7.348

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.